Matthias Stelljes
Overview
Explore the profile of Matthias Stelljes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
215
Citations
6023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schroeder T, Flossdorf S, Schuh C, Pabst C, Stadler M, Schetelig J, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40058648
Mutations in isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are found in 15% to 20% of patients with acute myeloid leukemia (AML). IDH inhibitors have been introduced as...
2.
Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 40016514
No abstract available.
3.
de Lima M, Kebriaei P, Lanza F, Cho C, Popradi G, Kaur M, et al.
Am J Hematol
. 2025 Feb;
PMID: 39989181
No abstract available.
4.
Jabbour E, Rousselot P, Gokbuget N, Chevallier P, Kantarjian H, Stelljes M
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39909815
The long-term outcome of older patients with acute lymphoblastic leukemia (ALL) is poor due to a reduced ability to tolerate intensive chemotherapy, a more aggressive disease biology, and the presence...
5.
Ronnacker J, Grau M, Klasmeier M, Klesse C, Baldauf H, Abert S, et al.
Blood
. 2025 Jan;
PMID: 39813679
Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germline variants APOE2, APOE3 and APOE4 give rise to three functionally distinct gene products. Previous studies reported yin-yang...
6.
Marks D, Cassaday R, Ribera J, Schuh A, Park J, Chiaretti S, et al.
Expert Rev Hematol
. 2025 Jan;
18(1):91-103.
PMID: 39778191
Introduction: Inotuzumab ozogamicin (InO) is indicated for the treatment of adults with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assessed outcomes by baseline characteristics...
7.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
Blood
. 2025 Jan;
PMID: 39775763
BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute...
8.
Duque-Afonso J, Finke J, Ngoya M, Galimard J, Schetelig J, Eder M, et al.
Bone Marrow Transplant
. 2024 Dec;
60(3):373-379.
PMID: 39702670
The treatment of relapsed/refractory acute myeloid leukemia (AML) is associated with a dismal prognosis. The allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed as salvage therapy. Reduced intensity conditioning protocols...
9.
Stelljes M
Hematology Am Soc Hematol Educ Program
. 2024 Dec;
2024(1):86-92.
PMID: 39644077
Antibody-based and cell-based novel immunotherapies, such as bispecific T-cell engagers (BiTE), antibody-drug conjugates, or chimeric antigen receptor (CAR) T cells are currently standard treatment options for patients with relapsed or...
10.
Bethge W, Flossdorf S, Hanke F, Schmid C, Ringhoffer M, Klein S, et al.
Haematologica
. 2024 Dec;
PMID: 39633549
We investigated the effect of center-specific variables on overall survival (OS) after allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML). Eligible were adult patients reported to DRST registry...